HistoSonics is a developer of a non-invasive robotics platform and novel beam therapy for non-thermal surgery that reduces patient trauma and healthcare costs across multiple indications.

HistoSonics' mission and passion is to advance the novel science of histotripsy and its powerful benefits, bringing meaningful and transformational change to physicians and their patients.

HistoSonics was founded in 2009 by Christine Gibbons, Jim Bertolina, Brian Fowlkes and Thomas Davison and is based in Ann Arbor, Michigan, with an office in Minneapolis, MN.


HistoSonics' flagship product, Robotically Assisted Sonic Therapy (RAST℠), offers a unique solution and significant promise to treat patients with a number of different diseases across global markets and care settings.


HistoSonics is currently focused on the development of its Edison™ platform, combining advanced imaging with proprietary sensing technology to deliver personalized external beam treatments with unparalleled precision and control, and with the promise of reducing many of the side effects of conventional therapies.


HistoSonics recently submitted safety and efficacy data from its #HOPE4LIVER Clinical Trials to the US Food and Drug Administration (FDA) and expects market authorization in 2023.


HistoSonics is backed by Johnson & Johnson Innovation – JJDC, Venture Investors, Varian Medical Systems, Signature Bank, Lumira Ventures, Yonjin Capital LLC, State of Wisconsin Investment Board, and others. The company raised $85M in a new round on Dec 13, 2022. This brings HistoSonics' total funding to $226.8M to date.



  • Year founded: 2009
  • Funding Info: $226.8M over 9 Rounds (Latest Funding Type: Series D)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Ann Arbor
  • State: Michigan
  • Country: United States
Related businesses